Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of deucravacitinib in biologic-naive active psoriatic arthritis
CTR20212237Phase 3Active
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of deucravacitinib in psoriatic arthritis (PsA), sponsored by Bristol Myers Squibb. Started Dec 2021; status: active.
02
Drugs
deucravacitinib
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on CTR20212237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212237.